Actively Recruiting
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Led by University of Southern California · Updated on 2026-03-16
40
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
University of Southern California
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
CONDITIONS
Official Title
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years
- Histopathologically or cytologically confirmed non-small cell lung cancer
- Currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, or Pembrolizumab with at least one cycle completed
- Previous chemotherapy, radiotherapy, targeted therapy, or immunotherapy allowed
- Ability and willingness to provide informed consent or have a surrogate decision maker provide consent
You will not qualify if you...
- Unable to consent for themselves
- Has not yet completed the first cycle of immune checkpoint inhibitor therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Los Angeles General Medical Center
Los Angeles, California, United States, 90033
Actively Recruiting
2
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here